AACR Cancer Progress Report 2012

[1]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[2]  Quality,et al.  National Healthcare Disparities Report , 2014 .

[3]  A. Argiris,et al.  Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Non-Small Cell Lung Cancer: A SEER Cohort Study , 2012, Annals of surgical oncology.

[4]  David A Fenstermacher,et al.  The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally , 2010, Clinical Cancer Research.

[5]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[6]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[7]  Graham A. Colditz,et al.  Applying What We Know to Accelerate Cancer Prevention , 2012, Science Translational Medicine.

[8]  T. Clackson,et al.  Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia , 2010, Clinical Cancer Research.

[9]  T. Nielsen,et al.  Pazopanib for metastatic soft-tissue sarcoma , 2012, The Lancet.

[10]  F. Saad,et al.  Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. , 2012 .

[11]  K. Straif,et al.  A review of human carcinogens--Part B: biological agents. , 2009, The Lancet. Oncology.

[12]  J. C. Meneghetti,et al.  Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Cook,et al.  Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk , 2012 .

[14]  B. Weber,et al.  Application of breast cancer risk prediction models in clinical practice. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Giaccone,et al.  Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  B. Thiers.  Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2008 .

[17]  M. Thun,et al.  Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women , 2002, Cancer Causes & Control.

[18]  J. Korte,et al.  Racial disparities in being recommended to surgery for oral and oropharyngeal cancer in the United States. , 2012, Community dentistry and oral epidemiology.

[19]  John Hornberger,et al.  US Insurance Program's Experience With a Multigene Assay for Early-Stage Breast Cancer. , 2011, Journal of oncology practice.

[20]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[21]  Akhil Wadhera,et al.  Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? , 2006, Dermatology online journal.

[22]  W. Foulkes,et al.  Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. , 1999, Journal of the National Cancer Institute.

[23]  T. Helbich,et al.  Magnetic Resonance Imaging of the Breast Improves Detection of Invasive Cancer, Preinvasive Cancer, and Premalignant Lesions during Surveillance of Women at High Risk for Breast Cancer , 2007, Clinical Cancer Research.

[24]  廣畑 富雄,et al.  Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective , 2007 .

[25]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[26]  V. Beral,et al.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls , 2008, The Lancet.

[27]  N. Day,et al.  TRENDS IN MORTALITY FROM CERVICAL CANCER IN THE NORDIC COUNTRIES: ASSOCIATION WITH ORGANISED SCREENING PROGRAMMES , 1987, The Lancet.

[28]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[29]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[30]  K. Mokbel,et al.  Risk-reducing strategies for women carrying brca1/2 mutations with a focus on prophylactic surgery , 2010, BMC women's health.

[31]  John A Thompson,et al.  Treatment of metastatic melanoma: an overview. , 2009, Oncology.

[32]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[33]  Paul S Mischel,et al.  Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. , 2012, Cancer discovery.

[34]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[35]  D. Hunter,et al.  Use of tanning beds and incidence of skin cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Qin,et al.  Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies , 2010, Breast Cancer Research and Treatment.

[37]  E. Hawk,et al.  Chemoprevention--history and general principles. , 2011, Best practice & research. Clinical gastroenterology.

[38]  Mary C. White,et al.  Cancer screening - United States, 2010. , 2012, MMWR. Morbidity and mortality weekly report.

[39]  Stacey A. Kenfield,et al.  Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. , 2011, Cancer research.

[40]  M. Roizen.  Obesity is an independent prognostic variable in colon cancer survivors , 2011 .

[41]  C. Garnett,et al.  U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis , 2012, Clinical Cancer Research.

[42]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[43]  Eric J Feuer,et al.  Projections of the cost of cancer care in the United States: 2010-2020. , 2011, Journal of the National Cancer Institute.

[44]  Kurt Straif,et al.  A review of human carcinogens--part D: radiation. , 2009, The Lancet. Oncology.

[45]  H. van de Velde,et al.  Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma , 2012, Haematologica.

[46]  J. Minna,et al.  ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. , 2010, Cancer cell.

[47]  Susan M. Domchek,et al.  Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.

[48]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[49]  Gail M Williams,et al.  Reduced melanoma after regular sunscreen use: randomized trial follow-up. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[51]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[52]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. D. de Bono,et al.  New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway , 2011, Clinical Cancer Research.

[54]  E. Riboli,et al.  The second expert report, Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective , 2007 .

[55]  M. Berger,et al.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.

[56]  T. Lash,et al.  Triple-negative breast cancers are increased in black women regardless of age or body mass index , 2009, Breast Cancer Research.

[57]  John T. Wei,et al.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. , 2011, The Journal of urology.

[58]  Michele Cavo,et al.  Proteasome inhibitors in multiple myeloma: 10 years later. , 2012, Blood.

[59]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[60]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[61]  Joseph P. Costantino,et al.  Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer , 2010, Cancer Prevention Research.

[62]  K. Straif,et al.  A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. , 2009, The Lancet. Oncology.

[63]  Luke A. Stewart,et al.  Leadership in Decline: Assessing U.S. International Competitiveness in Biomedical Research , 2012 .

[64]  Neil Swanson,et al.  Ingenol mebutate gel for actinic keratosis. , 2012, The New England journal of medicine.

[65]  Ahmedin Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2008, featuring cancers associated with excess weight and lack of sufficient physical activity , 2012, Cancer.

[66]  J. Richie,et al.  Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. , 2012 .

[67]  W. T. Vonstille,et al.  Radon and cancer , 1990 .

[68]  Robert Harris.  Cancer and the environment , 1970 .

[69]  Judith A. Smith,et al.  Clinical Perspectives on the Role of the Human Papillomavirus Vaccine in the Prevention of Cancer , 2011, Pharmacotherapy.

[70]  T. Eberlein.  Durable Complete Responses in Heavily Pretreated Patients with metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2012 .

[71]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[72]  Jacques Ferlay,et al.  The global burden of cancers attributable to infections in the year 2008: a review and synthetic analysis Web appendix section , 2012 .

[73]  Benjamin D Smith,et al.  Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Yin Cao,et al.  Body Mass Index, Prostate Cancer–Specific Mortality, and Biochemical Recurrence: a Systematic Review and Meta-analysis , 2011, Cancer Prevention Research.

[75]  Katherine M Flegal,et al.  Prevalence of obesity in the United States, 2009-2010. , 2012, NCHS data brief.

[76]  L. Newman,et al.  African ancestry and higher prevalence of triple‐negative breast cancer , 2010, Cancer.

[77]  J. Baselga,et al.  Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[79]  S. Nass,et al.  Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary , 2013 .

[80]  P. Moore,et al.  Merkel cell carcinoma: a virus-induced human cancer. , 2012, Annual review of pathology.

[81]  J. Thigpen,et al.  Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer , 2012 .

[82]  R. Gelber,et al.  Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.

[83]  M. Gordon.  Indoor Tanning and Risk of Melanoma: A Case-Control Study in a Highly Exposed Population , 2010 .

[84]  D. Coate,et al.  The Potential for Using Excise Taxes to Reduce Smoking , 1981, Journal of health economics.

[85]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[86]  S. Narod,et al.  Genetics of breast and ovarian cancer. , 1994, British medical bulletin.

[87]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[88]  C. Fletcher,et al.  Smoking and health. , 1970, WHO chronicle.

[89]  R. Pearson,et al.  Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .

[90]  Mark Schiffman,et al.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. , 2011, The Lancet. Oncology.

[91]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[92]  Falko Fend,et al.  Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma , 2007, Clinical Cancer Research.

[93]  E. Scarpi,et al.  Ipilimumab in advanced melanoma: reports of long-lasting responses , 2012, Melanoma research.

[94]  W. Orzechowski,et al.  Tax Burden on Tobacco , 2001 .

[95]  Laura M. Heiser,et al.  A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. , 2012, Cancer discovery.

[96]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[97]  K. Viswanath,et al.  Tobacco and cancer: an American Association for Cancer Research policy statement. , 2010, Cancer research.

[98]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[99]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[100]  B. Park,et al.  The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. , 2012, Future oncology.

[101]  Sameer M. Siddiqi,et al.  Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. , 2012, Journal of the National Cancer Institute.

[102]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[103]  Connie Lim,et al.  Youth risk behavior surveillance - United States, 2011. , 2012, Morbidity and mortality weekly report. Surveillance summaries.

[104]  Jeon Yeob Jang,et al.  Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer , 2009, Clinical Cancer Research.

[105]  A. Partin,et al.  ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. , 2011, Urology.

[106]  W. Hait.  Forty years of translational cancer research. , 2011, Cancer discovery.

[107]  F. Chaloupka,et al.  The Impact of the 2009 Federal Tobacco Excise Tax Increase on Youth Tobacco Use , 2012 .

[108]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[109]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[110]  S. Hariono,et al.  Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. , 2012, Cancer discovery.

[111]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[112]  Michael F. Rafferty.  Hit to lead , 2013 .

[113]  S. Larson,et al.  2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy , 2005, Clinical Cancer Research.

[114]  Office on Smoking.  How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General , 2010 .

[115]  K F WELLMANN,et al.  [SMOKING AND HEALTH. ON THE REPORT OF THE ADVISORY COMMITTEE TO THE SURGEON GENERAL OF THE PUBLIC HEALTH SERVICE]. , 1964, Deutsche medizinische Wochenschrift.

[116]  M. Carbone,et al.  Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma , 2011, Clinical Cancer Research.

[117]  M. Ychou,et al.  Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  M. Pishvaian,et al.  Current management of inflammatory bowel disease and colorectal cancer. , 2011, Gastrointestinal cancer research : GCR.

[119]  V. D. Ojeda,et al.  Racial and Ethnic Disparities in Access to Health Insurance and Health Care , 2000 .

[120]  S. Trudel,et al.  A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma , 2012, Clinical Cancer Research.

[121]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.